a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00130858

Enrollment

Registered

2005-08-16

Start date

2005-01-31

Completion date

2009-03-31

Last updated

2009-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma, Soft Tissue

Keywords

Sarcoma, Soft Tissue

Brief summary

Phase II Study to evaluate the response on two blocks of topotecan and carboplatin

Detailed description

Phase II study for patients with chemosensible soft tissue sarcoma stage IV in children and adolescents ; response according to RECIST criteria following two blocks of combination therapy consisting of Topotecan and carboplatin

Interventions

DRUGTopotecan

DRUGCarboplatin

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 21 Years

Healthy volunteers

Inclusion criteria

* Soft tissue sarcoma chemosensible, stage IV * age \< 21 * measurable tumor lesions

Exclusion criteria

* Lack of cooperation by the patient * no willingness of follow-up examinations * participation on another clinical trial at the same time * death due to the sickness within four weeks

Design outcomes

Primary

Measure	Time frame
Response according to RECIST criteria	—

Secondary

Measure	Time frame
Toxicity	—
Overall-Survival	—
Event-free-survival	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026